Physiotherapy Department, ,, Egaleo, School of Health & Care Sciences, University of West Attica, 12243, Greece.
F1000Res. 2024 Mar 19;12:1361. doi: 10.12688/f1000research.141455.2. eCollection 2023.
Diaphragm dysfunction is prevalent among individuals with asthma due to lung hyperinflation and hyperventilation in asthma paroxysm. This study was designed to evaluate the effect of the manual diaphragm release technique (MDRT) on diaphragm function in individuals with asthma.
Adults with diagnosed stable asthma (n = 24), will be recruited from the General Hospital of Kifissia "Agioi Anargyroi" in Athens, Greece. The volunteers who meet the inclusion criteria will be randomly allocated to two groups: (a) the experimental group (n = 12) that will receive 12 sessions of MDRT in conjunction with breathing retraining exercises (BRE), and (b) the control group (n = 12) that will receive 12 sessions of BRE. Measurements will occur at three time points: before the initiation of treatment sessions (week 0), followed by 12 treatment sessions (week 6), and three months from the beginning of the trial (week 12). The main outcomes will be the diaphragm excursion (ultrasonography) and chest expansion (inch tape), with secondary outcomes the maximal respiratory pressures (digital pressure manometer), dysfunctional breathing (Nijmegen questionnaire), asthma control (ACT), dyspnea (Borg scale) and quality of life (SF-12v2).
The proposed protocol is the first to examine the effectiveness of MRDT on diaphragm's function in individuals with asthma. Manual Therapy (MT) is a low-cost alternative and supplementary therapy to standard treatment procedures that might improve the biomechanics of respiration in pulmonary rehabilitation.
Registered on Clinical Trials.gov (ID: NCT05709054).
29/09/2023.
哮喘患者由于哮喘发作时肺部过度充气和过度通气，膈肌功能障碍较为常见。本研究旨在评估手动膈肌松解技术（MDRT）对哮喘患者膈肌功能的影响。
将从希腊雅典基菲西亚“Agioi Anargyroi”综合医院招募诊断为稳定期哮喘的成年人（n=24）。符合纳入标准的志愿者将被随机分配到两组：（a）实验组（n=12），将接受 12 次 MDRT 联合呼吸训练（BRE），和（b）对照组（n=12），将接受 12 次 BRE。测量将在三个时间点进行：在治疗开始前（第 0 周）、接受 12 次治疗后（第 6 周）和试验开始后三个月（第 12 周）。主要结果将是膈肌活动度（超声）和胸廓扩张（英寸带），次要结果将是最大呼吸压力（数字压力计）、呼吸功能障碍（尼姆斯根问卷）、哮喘控制（ACT）、呼吸困难（Borg 量表）和生活质量（SF-12v2）。
该方案是首次研究 MDRT 对哮喘患者膈肌功能的有效性。手动疗法（MT）是一种低成本的替代和补充标准治疗程序的治疗方法，可能改善呼吸康复中的呼吸生物力学。
ClinicalTrials.gov 注册（ID：NCT05709054）。
2023 年 9 月 29 日。
